3,700 Moderna, Inc. $MRNA Shares Bought by Ethic Inc.

Ethic Inc. boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 23.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,394 shares of the company’s stock after buying an additional 3,700 shares during the quarter. Ethic Inc.’s holdings in Moderna were worth $3,735,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its holdings in shares of Moderna by 8.8% in the third quarter. Parallel Advisors LLC now owns 5,082 shares of the company’s stock valued at $979,000 after purchasing an additional 410 shares during the period. Abacus Wealth Partners LLC bought a new position in Moderna in the third quarter worth approximately $259,000. Plancorp LLC bought a new position in Moderna in the third quarter worth approximately $210,000. May Hill Capital LLC purchased a new position in Moderna during the 3rd quarter worth $238,000. Finally, Heritage Family Offices LLP purchased a new position in Moderna during the 3rd quarter worth $253,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MRNA shares. Singular Research raised Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a research note on Wednesday, September 9th. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Loop Capital set a $135.00 price objective on Moderna in a report on Wednesday, August 19th. Finally, Bank of America upped their price objective on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus target price of $113.75.

Moderna Trading Down 6.8%

Moderna stock opened at $250.83 on Wednesday. The stock has a 50-day moving average price of $196.68 and a 200 day moving average price of $93.60. The company has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $280.80. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same quarter in the prior year, the company earned ($0.51) EPS. Moderna’s quarterly revenue was up 29.2% on a year-over-year basis. Sell-side analysts anticipate that Moderna, Inc. will post -5.69 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.